Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapix Biosciences Ltd ADR TRPXY

Healthcare Biotechnology
Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid... see more

Recent & Breaking News (OTCPK:TRPXY)

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  April 9, 2018

Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program

PR Newswire April 9, 2018

Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain

PR Newswire March 20, 2018

Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

PR Newswire February 7, 2018

Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018

PR Newswire January 9, 2018

Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

PR Newswire December 4, 2017

Therapix Biosciences Spotlighted in Financial and Trade Media Outlets

PR Newswire November 21, 2017

Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

PR Newswire November 10, 2017

Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update

PR Newswire November 9, 2017

Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders

GlobeNewswire November 7, 2017

Therapix to Present at and Attend Investor Conferences in London

PR Newswire November 7, 2017

Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017

PR Newswire November 2, 2017

Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer

PR Newswire November 2, 2017

Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd

PR Newswire October 30, 2017

Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center

PR Newswire October 30, 2017

Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea

PR Newswire October 18, 2017

Therapix Signs Formulation Development and Clinical Manufacturing Agreement with Catalent for THX-TS01

PR Newswire October 6, 2017

Therapix's First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study

PR Newswire September 27, 2017

Therapix Biosciences Second Quarter 2017 Conference Call and Webcast Scheduled for Thursday, August 10, 2017

PR Newswire August 3, 2017

CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

GlobeNewswire July 11, 2017